Site-directed serology of HIV-1 subtype B infection: Relation between virus specific antibody levels and disease progression Site-directed serology of HIV-1 subtype B infection: Relation between virus specific antibody levels and disease progression

Clinical and Experimental Immunology

Volumn 106, Issue 1, 1996, Pages 35-39

  Brostrom C ^a   Sonnerborg A ^a   Kim, S ^a   Sallberg M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HIV 1; Long term asymptomatics; Site directed serology; T helper cell dependently antibody

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN GP 41; VIRUS ANTIBODY;

ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEASLES VIRUS; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

EID: 0029781731     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-822.x     Document Type: Article

References (14)

1. + cell counts. J Infect Dis 1994; 169:1236 43.
2. Lange JMA, de Wolf, F, Goudsmit J. Markers for progression in HIV infection. AIDS 1989; 3:153 60.
3. Broström, C, Sönnerhorg A, Sällberg M. HIV-1 infected patients with no disease progression display a maintained high avidity antibody production to autologous V3 sequences. J Infect Dis 1995; 171:509 11.
4. Kliks SC, Shioda T, Haigwood NL, Levy JA. V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993; 90:1518 22.
5. Carmichael A, Jin X, Sissons P, Borysiewicz L. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein Barr virus in late disease. J Exp Med 1993; 177:249 56.
6. Sherefa K, Sällberg M, Sönnerborg A. Evidence of no change in V3 loop antibody recognition pattern in HIV type-1 infected Ethiopians between 1988 and 1993. AIDS Res Hum Retro 1994; 10:1547 52.
7. Myers G, Korber B, Berzofsky J, Smith R, Pavlakis G. Human retroviruses and AIDS database. Los Alamos National Laboratory, 1992.
8. Sällberg M, Rudén U, Magnius LO, Norrby E, Wahren B. Rapid 'tea-bag' peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett 1991; 30:59 68.
9. Sällberg M, Ruden U, Wahren B, Magnius LO. Immunodominant regions within the hepatitis C virus core and putative matrix proteins. J Clin Microbiol 1992; 30:1989 94.
10. Vuorimaa T, Arstila P, Ziola B, Salmi AA, Hanninen P, Halonen P. Solid-phase radioimmunoassay determination of virus-specific IgM antibody levels in a follow-up of patients with naturally acquired morbilli infections. J Med Virol 1978; 2:w271 8.
11. Hedman K, Vaheri A, Brummer M. Rapid diagnosis of hantavirus disease with an IgG-avidity assay. Lancet 1991; 338:1353 6.
12. Sönnerborg A, Ehrnst A, Strannegård Ö. Relationship between occurrence of virus in blood plasma and cerebrospinal fluid of HIV-infected individuals. J Med Virol 1989; 27:258 63.
13. Lee TH, Sheppard HW, Reis M, Dondero D, Osmond D, Busch MP. Circulating HIV-1 infected cell burden from seroconversion to AIDS: importance of postseroconversion viral load on disease course. J AIDS 1994; 7:381-8.
14. Bell KD, Ramilo O, Vitetta ES. Combined use of an immunotoxin and cyclosporine, to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virus. Proc Nat Acad Sci USA 1993; 90:1411 15.